| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
1-Palmitoyl-sn-glycerol 3-phosphate sodium salt does not have a single specific biological target but is involved in lipid metabolism and cell signaling. As a lysophosphatidic acid analog, it may interact with LPA receptors (LPA1-6) and other lipid-binding proteins. It is an endogenous metabolite involved in the regulation of various cellular processes, including cell proliferation, migration, and survival. It may also be involved in the pathogenesis of non-alcoholic fatty liver disease.
|
|---|---|
| ln Vitro |
In vitro studies of 1-Palmitoyl-sn-glycerol 3-phosphate sodium salt are limited. As an endogenous metabolite and LPA analog, it may be used in cell-based assays to study LPA receptor signaling and lipid metabolism. The compound may be used to investigate the role of lysophosphatidic acid in various cellular processes, including cell proliferation, migration, and inflammation. It may also be used in studies of non-alcoholic fatty liver disease.
|
| ln Vivo |
In vivo activity data for 1-Palmitoyl-sn-glycerol 3-phosphate sodium salt are limited. As an endogenous metabolite, it is involved in lipid metabolism and may play a role in the pathogenesis of non-alcoholic fatty liver disease. Further research is needed to evaluate its in vivo biological functions and potential therapeutic applications. The compound may be used in animal models of NAFLD to study its role in disease progression.
|
| Enzyme Assay |
In vitro enzyme assays for 1-Palmitoyl-sn-glycerol 3-phosphate sodium salt may involve studying its metabolism by lipid phosphatases and other enzymes involved in lipid metabolism. The compound may be used as a substrate to study the activity of enzymes such as lipid phosphate phosphatases (LPPs) and autotaxin (ATX). Receptor binding assays may be performed to study its interaction with LPA receptors.
|
| Cell Assay |
In vitro cell-based assays using 1-Palmitoyl-sn-glycerol 3-phosphate sodium salt typically involve treatment of cultured cells with the compound to study its effects on LPA receptor signaling. Cells may be treated with the compound, and downstream signaling pathways (e.g., MAPK, PI3K/AKT) are measured. Cell proliferation, migration, and survival assays may be performed to assess the functional effects of LPA receptor activation.
|
| ADME/Pharmacokinetics |
1-Palmitoyl-sn-glycerol 3-phosphate sodium salt has a molecular formula of C19H38NaO7P and a molecular weight of 432.46. The CAS number is 17618-08-5. The compound should be stored at -20°C, sealed and away from moisture. In solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month (sealed storage, away from moisture). It is soluble in water at 50 mg/mL (115.62 mM).
|
| Toxicity/Toxicokinetics |
The toxicity profile of 1-Palmitoyl-sn-glycerol 3-phosphate sodium salt is not extensively characterized, as it is an endogenous metabolite. It is generally considered safe for use in biochemical research. The compound is intended for research use only and is not approved for therapeutic use in humans. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
1-Palmitoyl-sn-glycerol 3-phosphate sodium salt (1-P-GPA sodium salt) (CAS 17618-08-5) is an endogenously produced metabolite. It may be utilized in the study of non-alcoholic fatty liver disease. It has a molecular formula of C19H38NaO7P and a molecular weight of 432.46. The compound is intended for research use only.
|
| Molecular Formula |
C19H38NAO7P
|
|---|---|
| Molecular Weight |
432.46
|
| Exact Mass |
432.225
|
| CAS # |
17618-08-5
|
| Related CAS # |
1-Palmitoyl lysophosphatidic acid;22002-85-3;1-Palmitoyl-sn-glycerol 3-phosphate;7220-34-0
|
| PubChem CID |
87295007
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.919
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
29
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])[O-])O.[Na+].[Na+]
|
| InChi Key |
HKLKSZPQSFPBDE-JPKZNVRTSA-L
|
| InChi Code |
InChI=1S/C19H39O7P.2Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(21)25-16-18(20)17-26-27(22,23)24;;/h18,20H,2-17H2,1H3,(H2,22,23,24);;/q;2*+1/p-2/t18-;;/m1../s1
|
| Chemical Name |
disodium;[(2R)-3-hexadecanoyloxy-2-hydroxypropyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3124 mL | 11.5618 mL | 23.1235 mL | |
| 5 mM | 0.4625 mL | 2.3124 mL | 4.6247 mL | |
| 10 mM | 0.2312 mL | 1.1562 mL | 2.3124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA